FDA Approved: BYOOVIZ — Supplemental Application (BIOGEN INC.)

View source ↗

Summary

FDA approved a supplemental application for BYOOVIZ (ranibizumab-nuna) from Biogen, updating its labeling with additional indications for ocular diseases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Diabetic Retinopathy
• Macular Edema Following Retinal Vein Occlusion
• Neovascular Age-related Macular Degeneration

Drugs mentioned

• BYOOVIZ (ranibizumab-nuna)

Snippet

SUPPL AP for BYOOVIZ (RANIBIZUMAB-NUNA)